GondolaBio’s cover photo
GondolaBio

GondolaBio

Biotechnology Research

Palo Alto, California 5,049 followers

Creating new and meaningful medicines for patients with genetic diseases

About us

GondolaBio is a clinical-stage biopharmaceutical company focused on developing novel medicines for patients living with genetic diseases. A sister company of BridgeBio Pharma, GondolaBio aims to leverage cutting-edge biological research to create breakthrough medicines addressing high unmet needs across multiple therapeutic areas, modalities, and stages ranging from early discovery to clinical development. Its team of experienced drug discoverers, developers and innovators are committed to translating advances in genetic science into medicines that can help patients as quickly as possible.

Website
https://gondolabio.com/
Industry
Biotechnology Research
Company size
11-50 employees
Headquarters
Palo Alto, California
Type
Privately Held
Founded
2024

Locations

Employees at GondolaBio

Updates

  • “What drives me is a love of life. I want to experience everything, even though I’ve got porphyria.”   Today is #GlobalPorphyriaDay. Pete was diagnosed with #ErythropoieticProtoporphyria (EPP) at just two years old. Living with EPP means navigating a life where even brief exposure to sunlight can trigger excruciating pain and swelling. For Pete, this means avoiding sunlight and taking significant precautions to protect his skin, like using blinds, traveling at night and wearing protective clothing.   Wearing full protective clothing outdoors can also come with an emotional toll. Pete knows he is often seen as different, and the attention, stares, and negative interactions that come with needing to fully cover up can make everyday situations feel uncomfortable and isolating.   Despite these challenges, Pete’s story is one of resilience, adaptation, and determination to keep moving forward without letting EPP define his life.   We’re grateful to Pete and the British Porphyria Association for bringing his EPP story to light and helping raise awareness for the community.

  • Today marks World #NF1AwarenessDay, a life-altering genetic condition that can present in both visible and invisible ways. Listen below as Aaron shares his experience living with NF1, reflecting on the challenges and resilience that have shaped his journey. From navigating social pressures at a young age to making a massive decision that ultimately improved his quality of life, his journey is a reminder that no two experiences are the same. At GondolaBio, we’re committed to working on behalf of the NF1 community and re-engineering the future of NF1 disease management.

  • May is #TSCAwarenessMonth. To kick off this important month, we’re honored to continue sharing Riona’s story. Tuberous Sclerosis Complex (TSC) is a rare, genetic condition that can affect multiple body systems such as the skin, eyes, brain, kidneys, heart, and lungs. Despite many daily challenges, Riona's family enjoys an active life together and remains hopeful for the future. In this short film, we see more of what living with TSC is like. View more of Riona's story here. https://lnkd.in/eGkhN_BV Thank you again to the TSC Alliance for helping us share Riona’s story.

  • This weekend, the GondolaBio team attended the FD/MAS Alliance Research Priorities Workshop in Philadelphia! This meeting brought together clinicians, researchers, and patients and caregivers impacted by fibrous dysplasia and McCune-Albright Syndrome to shape the FD/MAS research agenda and identify the most pressing needs. Thank you to all who made this a successful gathering.

    • No alternative text description for this image
    • No alternative text description for this image
  • View organization page for GondolaBio

    5,049 followers

    Putting patients first isn’t just a value at GondolaBio, it’s how we approach every decision, every program, and every step forward. We’re driven by the urgency of unmet need and the responsibility to translate science into therapies that truly matter, especially for those living with rare and underserved genetic conditions. Our work is grounded in the belief that innovation succeeds only if it improves real lives. This starts with listening to lived experience and ensuring those insights actively shape the therapies we develop. Because we believe in building alongside the communities we serve, not just for them.

  • We are proud to be a platinum sponsor of this week’s Mission: Cure Moments of Hope gala. #Pancreatitis is a devastating disease with limited treatment options, and we share the urgency to change that. We invite the community to join us at this free virtual event. Find more details from Mission: Cure below.

    View organization page for Mission: Cure

    588 followers

    Pancreatitis affects millions of people worldwide. Most patients spend years being misdiagnosed with limited treatment options and no cure. That's shifting. More therapies in development. More clinical trials underway. More progress than ever before. Mission: Cure's Moments of Hope Gala is where the pancreatitis community comes together every year to celebrate that progress and raise the funds that keep it moving. We will honor Vin Cataldo with our Hope Award for his significant contributions to our mission. You're invited — we'd love to have you there. 📅 Thursday, April 30 | 8:45 PM ET / 5:45 PM PT 🎟️ Register free: cure26.givesmart.com Thank you to our Platinum and Gold Sponsors— your support is driving this mission forward: GondolaBio, Kirkland & Ellis, Regenerative Medical Solutions, Inc., and Blue Owl Capital #Pancreatitis #RareDisease #ChronicPancreatitis

    • No alternative text description for this image
  • This weekend, we joined the TSC Alliance at the 25th annual Comedy for a Cure at the Irvine Improv! Each year, this event raises awareness and funds to advance research and support for the #TSC community, with a little good-humored fun along the way. We are honored to support this event and TSC Alliance's mission.  

    • No alternative text description for this image

Similar pages

Browse jobs

Funding

GondolaBio 1 total round

Last Round

Series unknown

US$ 300.0M

See more info on crunchbase